Key Takeaways Abbott gained CE Mark for Navitor TAVI to treat low and intermediate-surgical risk patients.Abbott's expanded approval broadens access across all surgical risk categories in Europe.ABT's VANTAGE trial data showed strong safety, no 30-day deaths, and excellent valve performance.Abbott Laboratories (ABT) recently received CE Mark in Europe for an expanded indication for its Navitor transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who ...